Spero Therapeutics Appoints Dr. Debra Jeske Zack as CMO to Lead Phase 2-Ready Anti-CD40L Antibody SP001
核心洞察
Spero Therapeutics has appointed Debra Jeske Zack, M.D., Ph.D., a board-certified rheumatologist with over 25 years of experience, as chief medical officer.
Dr. Zack will lead the clinical development strategy for SP001, a Phase 2-ready third-generation anti-CD40L (搜索) monoclonal antibody targeting IgG4-related disease (搜索).
SP001 is a fully humanized, Fc-silent IgG1 antibody designed to inhibit CD40L (搜索) while addressing platelet activation concerns seen with earlier anti-CD40L therapies.
Spero Therapeutics has appointed Debra Jeske Zack, M.D., Ph.D., as chief medical officer, bringing aboard an experienced immunology and rheumatology executive as the Cambridge, Massachusetts-based company prepares to advance its lead antibody program into clinical development. Dr. Zack will lead the clinical development strategy and organization, strengthening the leadership team as Spero readies SP001, a Phase 2-ready third-generation anti-CD40L (搜索) antibody, for studies in IgG4-related disease (搜索) (IgG4-RD) and other immune-mediated conditions.
President and Chief Executive Officer Esther Rajavelu said Dr. Zack joins the company at a pivotal point as clinical development of SP001 begins. Rajavelu cited Zack's experience in rheumatology, immunology, and autoimmune drug development as important to shaping Spero's clinical strategy and advancing therapies for patients with significant unmet medical needs.
A Seasoned Clinician-Scientist at the Helm
Dr. Zack is a board-certified rheumatologist with a doctorate in immunology and more than 25 years of experience spanning research, clinical development, and medical affairs. Most recently, she served as chief medical officer at Exagen Inc. Before that, she held clinical leadership positions at Xencor Inc. and within Novartis' Biotherapeutics Development Unit.
Earlier in her career, Dr. Zack served as global development lead for Enbrel at Amgen, where she also held roles across preclinical research, clinical development, and medical affairs. Prior to joining the biopharmaceutical industry, she spent a decade as an associate professor at the University of California, Los Angeles, treating patients with rheumatic diseases while conducting molecular immunology research. She earned her M.D. and Ph.D. from the University of Texas Southwestern Medical School and completed her residency and rheumatology fellowship at the UCLA School of Medicine.
SP001: A Differentiated Approach to Immune-Mediated Disease
Commenting on her appointment, Dr. Zack said SP001 offers a differentiated approach to treating immune-mediated diseases by targeting CD40 ligand, a signaling pathway involved in activating both B cells and T cells. She noted that the mechanism has the potential to address multiple drivers of diseases such as IgG4-related disease (搜索) and expressed enthusiasm about leading the program's clinical development while helping shape future pipeline opportunities.
SP001 is a fully humanized, Fc-silent IgG1 monoclonal antibody designed to inhibit CD40L (搜索), an upstream regulator of immune activation involved in T-cell, B-cell, antigen-presenting cell, and platelet biology. Spero is developing the therapy as a targeted, non-B-cell-depleting treatment for immune-mediated diseases where immune cell interactions contribute to chronic inflammation, fibrosis, and disease progression.
The antibody is also designed to address platelet activation concerns associated with earlier generations of anti-CD40L (搜索) therapies while maintaining the extended half-life characteristics of conventional monoclonal antibodies. By preserving FcRn interaction that supports IgG-like half-life, SP001 aims to combine the therapeutic benefits of CD40L blockade with an improved safety profile.
Pipeline and Corporate Outlook
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for immunology and inflammatory diseases. Its lead candidate, SP001, is initially being developed for IgG4-related disease (搜索), with potential applications across additional immune-mediated disorders. The company trades on the Nasdaq under the ticker symbol SPRO.